EW ▼ -3.3% - Edwards Lifesciences Corporation
$EW Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
02-NOV-2026 12:40 PM ET
Share this post
More filings for $EW
EW ▲ +0.6% - Edwards Lifesciences CorporationNov 2, 2026EW ▼ -3.3% - Edwards Lifesciences CorporationNov 2, 2026EW ▼ -0.5% - Edwards Lifesciences CorporationOct 21, 2026EW ▼ -0.5% - Edwards Lifesciences CorporationOct 21, 2026EW ▼ -0.0% - Edwards Lifesciences CorporationOct 7, 2026EW ▲ +0.3% - Edwards Lifesciences CorporationOct 5, 2026
View full $EW filing history →💬 Comments
Loading comments…
Leave a comment